Lumiliximab
Encyclopedia
Lumiliximab is a monoclonal antibody that targets CD23
. It acts as an immunomodulator
and, , it is being investigated in Phase I and II clinical trials for the treatment of chronic lymphocytic leukemia
. The drug is a chimeric antibody from Macaca irus and Homo sapiens.
CD23
CD23, also known as Fc epsilon RII, or FcεRII, is the "low-affinity" receptor for IgE, an antibody isotype involved in allergy and resistance to parasites, and is important in regulation of IgE levels. Unlike many of the antibody receptors, CD23 is a C-type lectin...
. It acts as an immunomodulator
Immunomodulator
An immunomodulator, also known as an immunotherapy is a substance which has an effect on the immune system.- Immunosuppressants :Inhibits immune response in organ transplantation and autoimmune diseases.- Immunostimulants :...
and, , it is being investigated in Phase I and II clinical trials for the treatment of chronic lymphocytic leukemia
Chronic lymphocytic leukemia
B-cell chronic lymphocytic leukemia , also known as chronic lymphoid leukemia , is the most common type of leukemia. Leukemias are cancers of the white blood cells . CLL affects B cell lymphocytes. B cells originate in the bone marrow, develop in the lymph nodes, and normally fight infection by...
. The drug is a chimeric antibody from Macaca irus and Homo sapiens.